Ibrutinib (PCI-32765)

For research use only. Not for use in humans.

製品コードS2680

CAS No. 936563-96-1

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

サイズ

価格(税別)

10mM (1mL in DMSO)	JPY 47100
5mg	JPY 30200
50mg	JPY 163000
200mg	JPY 412000

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297 | 電子メール：[email protected]

文献中Selleckの製品使用例(423)

製品安全説明書

Target Protein Ligand阻害剤の選択性比較

生物活性

製品説明

ターゲット

BTK ^[1] (Cell-free assay)	BLK ^[1] (Cell-free assay)	Bmx ^[1] (Cell-free assay)	CSK ^[1] (Cell-free assay)	FGR ^[1] (Cell-free assay)	もっとクリックする
0.5 nM	0.5 nM	0.8 nM	2.3 nM	2.3 nM	もっとクリックする

体外試験

Ibrutinib shows the potent and irreversible inhibitory effect and selectivity for Btk enzymatic activity. In BCR pathway-activated DOHH2 cell line, Ibrutinib inhibits autophosphorylation of Btk, phosphorylation of Btk's physiological substrate PLCγ, and phosphorylation of further downstream kinase, ERK with IC50 of 11 nM, 29 nM and 13 nM, respectively. ^[1] Ibrutinib exhibits a significant dose-dependent and time-dependent induction of cytotoxicity in chronic lymphocytic leukemia (CLL) cells. In addition, Ibrutinib induces cell death depending on caspase pathway activation and antagonizes the ability of CLL cells to proliferate after TLR signaling. ^[2] A recent study shows that Ibrutinib inhibits BCR-activated primary B cell proliferation with IC50 of 8 nM and results in inhibition of TNFα, IL-1β and IL-6 production in primary monocytes with IC50 of 2.6 nM, 0.5 nM and 3.9 nM, respectively. ^[3]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
human Rec1 cells	M1LaSmZ2dmO2aX;uJIF{e2G7	MUKyMlUh\|ryP	MnPROkBp	MX\Jcohq[mm2aX;uJI9nKEy7bjDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iUnXjNUBk\WyuczDheEAzNjVidV2gbY5kfWKjdHXkJIZweiB4IHjyd{BjgSCZZYP0[ZJvKGKub4T0bY5oKG2ndHjv[C=>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ{Mki3O{c,OjV{MkK4O\|c9N2F-
human WSU-NHL cells	MYPDfZRwfG:6aXRCpIF{e2G7		NXvaUZVlPzJiaB?=	M1TrOmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHdUXS2QSFygZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdnRiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6wPUDPxE1?	NF7U[2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
human SU-DHL6 cells	NYPCXFNoS3m2b4TvfIlkyqCjc4PhfS=>		MY[3NkBp	MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTWU1FUEx4IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIx2dWmwZYPj[Y51KGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwNUig{txONg>?	NXjZeFlYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
human DOHH2 cells	Mk\6R5l1d3SxeHnjxsBie3OjeR?=		NVXTUHJYPzJiaB?=	MYfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEU2hJOiClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDseY1qdmW\|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjRzIN88UU4>	M1L6dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NlkyLz5{NEmxOVI6OTxxYU6=
Sf9 cells	M1;Qe2Z2dmO2aX;uJIF{e2G7		Mk\uNUBp	MWfJcohq[mm2aX;uJI9nKEy\Tj3BJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiYX\0[ZIhPjBibXnud{BjgSCWUj3GVmVVKEG\|c3H5MEBKSzVyPUCuNkDPxE1w	NWPFUlhWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVg2PDdpPkKxPVU5PTR5PD;hQi=>
human Ramos cells	MmC4SpVv[3Srb36gZZN{[Xl?		NWXpWlJGOSCq	Mo\ITY5pcWKrdHnvckBw\iCEdHugbY4hcHWvYX6gVoFud3NiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBRVENvZ3HtcYEzKHCqb4PwbI9zgWyjdHnvckBifCCWeYKxNlE4KGGodHXyJFEhcHJiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{NCCLQ{WwQVE1KG6PLh?=	M2LRRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NlkyLz5{NEmxOVI6OTxxYU6=
human Pfeiffer cells	NVjvRpZOTnWwY4Tpc44h[XO\|YYm=		M4D3d\|czKGh?	MWDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQ[oVq\m[ncjDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{IH7NMi=>	NInVUWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
Sf9 cells	Mn3NSpVv[3Srb36gZZN{[Xl?		NXrENJdbOSCq	NYjONlJnUW6qaXLpeIlwdiCxZjDoeY1idiCodXzsMYxmdme2aDDCWGsh\XiycnXzd4VlKGmwIGPmPUBk\WyuczD1d4lv\yCIQV2tV5JkfGmmZTDw[ZB1cWSnIHHzJJN2[nO2cnH0[UBi\nSncjC2NEBucW6\|IHL5JHRTNU[URWSgRZN{[XoxvJygTWM2OD1yLkWgcm0v	M4DLcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUW4OVQ4Lz5{MUm1PFU1PzxxYU6=
Sf9 insect cells	MWXGeY5kfGmxbjDhd5NigQ>?		MoLXOlAhdWmwcx?=	NWHlNZBmUUN3MDC9JFAvODByMzFOwG0>	NF7KSIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG0OlE{Pid-MkmxOFYyOzZ:L3G+
sf9 cells	MV3GeY5kfGmxbjDhd5NigQ>?			MY\JR\|UxKD1iMD6wNFA{KM7:TR?=	NV7hXld2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVQ4OzZpPkK3PVk1PzN4PD;hQi=>
Sf9 insect cells	NHjuUVlHfW6ldHnvckBie3OjeR?=		MlP0OlAhdWmwcx?=	M33oW2lEPTBiPTCwMlAxODN2IN88US=>	NFPScJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxNlE4PSd-Mke5NVIyPzV:L3G+
Sf9 insect cells	MVHGeY5kfGmxbjDhd5NigQ>?		M1zCUVYxKG2rboO=	MYLJR\|UxKD1iMD6wNFA{PCEQvF2=	MoKwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{K5OFYoRjJ6NEOyPVQ3RC:jPh?=
Sf9 insect cells	NULoRVIzTnWwY4Tpc44h[XO\|YYm=		NUP4PGU4PjBibXnudy=>	NVHtZ2d4UUN3MDC9JFAvODByM{Sg{txO	NXzJNlk6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5OVYxOzdpPkK3PVU3ODN5PD;hQi=>
Sf9 cells	NG[1UHFHfW6ldHnvckBie3OjeR?=		M1\ZS\|YxKG2rboO=	M3jXXGlEPTBiPTCwMlAxODRizszN	NEXBOI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MECwOlE1Oyd-M{CwNFYyPDN:L3G+
Sf9 cells	M3PKTmZ2dmO2aX;uJIF{e2G7		NWjERVdiPjBibXnudy=>	M4\0XWlEPTBiPTCwMlAxODVizszN	NF24cZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm1PFU1Pyd-MkG5OVg2PDd:L3G+
Ramos cells	Ml7FSpVv[3Srb36gZZN{[Xl?		MYWxJIg>	NGrIV4pKSzVyIE2gNE4xODB3IN88US=>	NYi0Zox5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFAzPjFpPkK4NlgxOjZzPD;hQi=>
Sf9 cells	MU\GeY5kfGmxbjDhd5NigQ>?		NEO3[pM3OCCvaX7z	MU\JR\|UxKD1iMD6wNFEh\|ryP	M4eyRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe3OlA5Lz5\|MEC3O\|YxQDxxYU6=
Pfeiffer cells	NFrIdHZEgXSxdH;4bYNqfHliYYPzZZk>		Mm\LO\|IhcA>?	MV3HTVUxKD1iMD6wNFIh\|ryP	MoC3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
B cells	NXHTPXhXTnWwY4Tpc44h[XO\|YYm=		MWWxJIg>	M1zteGlEPTBiPTCwMlAxPDZizszN	NYDSb\|RjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyPVA6QDhpPkOwNlkxQTh6PD;hQi=>
Sf9 insect cells	M3TxdGZ2dmO2aX;uJIF{e2G7		MlK1NkB1dyB4MDDtbY5{	MWDLbUA:KDBwMEC0PEDPxE1?	M1jNPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
Ramos cells	MnrESpVv[3Srb36gZZN{[Xl?		M2G2WFEhcA>?	NGjubVlKSzVyIE2gNE4xODd3IN88US=>	NVrFZYNNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
Sf9 insect cells	MXfGeY5kfGmxbjDhd5NigQ>?		NF7HSFI3OCCvaX7z	M33OPGlEPTBiPTCwMlAxQCEQvF2=	NIrFeWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
TMD8 cells	M1j0W2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M2jl[lczKGh?	Moj4TWM2OCB;IECuNFEh\|ryP	M{j2VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{G1NFI{Lz5{OUexOVAzOzxxYU6=
CD19+ B cells	M174OGZ2dmO2aX;uJIF{e2G7		NEHPOFkyKGh?	MkjETWM2OCB;IECuNFEzKM7:TR?=	NGHsdXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS1O\|k5Oid-Mkm0OVc6QDJ:L3G+
Sf9 insect cells	MXTGeY5kfGmxbjDhd5NigQ>?		MWC2NEBucW6\|	MVzJR\|UxKD1iMD6wNVIh\|ryP	Mn;PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
Ramos cells	NY\VTWtxTnWwY4Tpc44h[XO\|YYm=		NUXVSWQ2OSCq	NH;OOlZKSzVyIE2gNE4xOTRizszN	M3PH[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NlkyLz5{NEmxOVI6OTxxYU6=
Sf9 insect cells	M{jMNWZ2dmO2aX;uJIF{e2G7		Mn;wNUBp	MVTJR\|UxKD1iMD6wNVQ1KM7:TR?=	MlezQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5MUWwNlMoRjJ7N{G1NFI{RC:jPh?=
Sf9 insect cells	Mnu1SpVv[3Srb36gZZN{[Xl?		NIXXbnY3OCCvaX7z	NXfPVWp{UUN3MDC9JFAvODF4MTFOwG0>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF2NkGzOkc,OjlzNE[xN\|Y9N2F-
HCC827 cells	M3TxeWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MY[3NkBp	MUPJR\|UxKD1iMD6wN\|kh\|ryP	MknWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5M{S1PFEoRjJ6N{O0OVgyRC:jPh?=
PC9 cells	NHvHOZpHfW6ldHnvckBie3OjeR?=		M2jJdFczKGh?	M3LabmdKPTBiPTCwMlA2KM7:TR?=	MkHxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
Sf9 cells	M13SUWZ2dmO2aX;uJIF{e2G7		NYq5Z5Z{PjBibXnudy=>	M2fNZ2lEPTBiPTCwMlEh\|ryP	MkXmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xOFMoRjNyMEC2NVQ{RC:jPh?=
H3255 cells	MnfBSpVv[3Srb36gZZN{[Xl?		MoLlO\|IhcA>?	Mlz2S2k2OCB;IECuNVEh\|ryP	NE\zNlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
BaF3 cells	MoruSpVv[3Srb36gZZN{[Xl?		MmnzO\|IhcA>?	M3L0bmdKPTBiPTCwMlEzKM7:TR?=	NITGdnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[zNFU2Oyd-Mk[2N\|A2PTN:L3G+
BAF3 cells	Mke0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NG\2SmU4OiCq	M2fMT2dKPTBiPTCwMlEzKM7:TR?=	Ml7PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
Sf9 insect cells	M4TiXWZ2dmO2aX;uJIF{e2G7		MXy2NEBucW6\|	M1LldmlEPTBiPTCwMlEzOyEQvF2=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh\|MUW1PVc9N2F-
Sf9 insect cells	NXnX[GpDTnWwY4Tpc44h[XO\|YYm=		M4qyS\|YxKG2rboO=	M4HFeGlEPTBiPTCwMlE1PiEQvF2=	M1vQUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
BAF3 cells	MWXGeY5kfGmxbjDhd5NigQ>?		MlP6O\|IhcA>?	MkThS2k2OCB;IECuNVYh\|ryP	M2DyUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
Sf9 cells	NYLiSFdsTnWwY4Tpc44h[XO\|YYm=		MVi2NEBucW6\|	MYfJR\|UxKD1iMD6yJO69VQ>?	NXnuRmR5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVg2PDdpPkKxPVU5PTR5PD;hQi=>
MV411 cells	NVnLU3p1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			Mn23S2k2OCB;IECuNlUh\|ryP	M1XRbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
MV4-11 cells	NIrJSm9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MlzOO\|IhcA>?	NX;RTHhkT0l3MDC9JFAvOzNizszN	MnHyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4M{C1OVMoRjJ4NkOwOVU{RC:jPh?=
MV4-11 cells	MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		M2r4R\|czKGh?	NVjJbYJ1T0l3MDC9JFAvOzNizszN	Mn3UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
DOHH2 cells	NEfxb4tEgXSxdH;4bYNqfHliYYPzZZk>		Ml\hO\|IhcA>?	M3rtbmdKPTBiPTCwMlQyKM7:TR?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
HCC827 cells	NELIWnNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MmPzPVYhcA>?	MYnFR\|UxKD1iMD60OUDPxE1?	MojhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O\|UoRjJ6OEWzOVc2RC:jPh?=
SU-DHL6 cells	NYG0UpY4S3m2b4TvfIlkcXS7IHHzd4F6		NHz6XXY4OiCq	NI\4[XpIUTVyIE2gNE42QCEQvF2=	M3\Ec\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NlkyLz5{NEmxOVI6OTxxYU6=
M07e cells	M33PS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NELCemxIUTVyIE2gNE42QSEQvF2=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh\|MUW1PVc9N2F-
NCI-H1975 cells	MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		M4O1d\|k3KGh?	NFrTcGNGSzVyIE2gNE43PCEQvF2=	NYT2fYVURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
SU-DHL-2 cells	M3raWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MnW4S2k2OCB;IECuOlQh\|ryP	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh\|MUW1PVc9N2F-
HEK293T cells	MojhSpVv[3Srb36gZZN{[Xl?		MYCxJIg>	MoH1TWM2OCB;IECuPUDPxE1?	NILpXHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NFI3OSd-MkiyPFAzPjF:L3G+
Ramos cells	NV3WUVV5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MXe3NkBp	MnHqTWM2OCB;IECuPVIh\|ryP	M2LWZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{G1NFI{Lz5{OUexOVAzOzxxYU6=
BA/F3 cells	M13CV2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MnroO\|IhcA>?	MXTJR\|UxKD1iMTFOwG0>	NWfiPW1[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVg2OjFpPkK2NlU5PTJzPD;hQi=>
WSU-NHL cells	NHi4UHpEgXSxdH;4bYNqfHliYYPzZZk>		NGj6fow4OiCq	M2PJXWdKPTBiPTCxMlA6KM7:TR?=	NYexfmxNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
NCI-H1975 cells	M3W3ZWZ2dmO2aX;uJIF{e2G7		M2TOSVczKGh?	NV2xOWt2T0l3MDC9JFEvOiEQvF2=	NFzYXGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
NCI-H1975 cells	M{C0VWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M1jiNVczKGh?	MmXDTWM2OCB;IEGuNlch\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd\|NEW4NUc,Ojh5M{S1PFE9N2F-
Raji cells	M{S0PGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MWe0PEBp	NGi3UopKSzVyIE2gNU41QSEQvF2=	M3zvTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NU[3Nlk2Lz5{OUW2O\|I6PTxxYU6=
Pfeiffer cells	NGi3WmNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NHvJeWZIUTVyIE2gNU43KM7:TR?=	M3fmXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
A431 cells	MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MmW4PVYhcA>?	MYDFR\|UxKD1iMj6zPEDPxE1?	MlWzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O\|UoRjJ6OEWzOVc2RC:jPh?=
BAF3 cells	NVHrbYhmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M17yTFczKGh?	M3HJXmdKPTBiPTCyMlUh\|ryP	M2H3OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
U937 cells	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NHjzWWFIUTVyIE2gNk46KM7:TR?=	NUjZc\|hpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N\|E2PTl5PD;hQi=>
NB4 cells	M{fXR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MkTMS2k2OCB;IEOg{txO	NWHTV3ViRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N\|E2PTl5PD;hQi=>
Ramos cells	NIHsPJdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MojGS2k2OCB;IEOuOEDPxE1?	NGXQ[\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
SKM1 cells	NX31OphvT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MVnHTVUxKD1iMz62JO69VQ>?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh\|MUW1PVc9N2F-
U2932 cells	M2q2[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NGfNZXhIUTVyIE2gOE41KM7:TR?=	M3WweFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
Ramos cells	MkfTRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M3rCXVczKGh?	MWfJR\|UxKD1iNT6xOEDPxE1?	MoXWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xOFMoRjNyMEC2NVQ{RC:jPh?=
Ramos cells	M1r0[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MXq0PEBp	Ml35TWM2OCB;IEWuNVQh\|ryP	NGWy[Zg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m1OlA{Pyd-Mke5OVYxOzd:L3G+
Ramos cells	NG\JPZRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NF;QepE1QCCq	NFvTdmlKSzVyIE2gOU45QCEQvF2=	M2PIcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOyPVQ3Lz5{OESzNlk1PjxxYU6=
Ramos cells	M{nHcGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NGnkRYU4OiCq	MXjJR\|UxKD1iNj62NkDPxE1?	NFTUcZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG0OlE{Pid-MkmxOFYyOzZ:L3G+
K562 cells	Ml2wRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NXXp[HFYPDhiaB?=	NGXHTHBKSzVyIE2gO{42KM7:TR?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5N{[wPEc,OzByN{e2NFg9N2F-
HL60 cells	MkPjRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MnHpOFghcA>?	NFnCcWFKSzVyIE2gPEDPxE1?	NIj2ToU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC3O\|YxQCd-M{CwO\|c3ODh:L3G+
Ramos cells	MmfsRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NIO5W4s1QCCq	M{DkOmlEPTBiPTC4MlEyKM7:TR?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOkc,Ojd7OUS3N\|Y9N2F-
Ramos cells	M1PWVGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MWW0PEBp	M1fwNmlEPTBiPTC4MlI3KM7:TR?=	MoThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3NkeyPVUoRjJ7NU[3Nlk2RC:jPh?=
OCI-AML3 cells	MnPDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MVnHTVUxKD1iOT6yJO69VQ>?	NVHhS41bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N\|E2PTl5PD;hQi=>
BAF3 cells	MmTtR5l1d3SxeHnjbZR6KGG\|c3H5		MlzvO\|IhcA>?	M4\n[2dKPTBiPTCxNEDPxE1?	NIG3[WQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[zNFU2Oyd-Mk[2N\|A2PTN:L3G+
BAF3 cells	NEnic3RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NXWxXVh2PzJiaB?=	NYjpdGJET0l3MDC9JFExKM7:TR?=	M1Lje\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
BAF3 cells	NHj0cFJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MV23NkBp	MVnHTVUxKD1iMUCg{txO	NVX3enZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
NAMALWA cells	NIrjbI5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MXK3NkBp	NWrIbnU5UUN3MDC9JFExNjR3IN88US=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF2NkGzOkc,OjlzNE[xN\|Y9N2F-
Ramos cells	NWe0PJJRSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NXfZPWo3PDhiaB?=	NFnUbYJKSzVyIE2gNVIvPiEQvF2=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzlzMkG3OUc,Ojd7MUKxO\|U9N2F-
Raji cells	M4XQ[WFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M3LiUlQ5KGh?	M2PBemlEPTBiPTCxOE4zKM7:TR?=	NHvRbGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC3O\|YxQCd-M{CwO\|c3ODh:L3G+
Raji cells	MVLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MVy0PEBp	M{jnbWlEPTBiPTCxOU4zKM7:TR?=	Mn;qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N\|YoRjJ5OUm0O\|M3RC:jPh?=
MIAPaCa2 cells	NILBb4pEgXSxdH;4bYNqfHliYYPzZZk>		MW[zJIRigXN?	MVfJR\|UxKD1iMU[uOkDPxE1?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB5N{KyPEc,OjdyN{eyNlg9N2F-
HeLa cells	NVPQTGtuS3m2b4TvfIlkcXS7IHHzd4F6		MV6zJIRigXN?	M4\HUWlEPTBiPTCxOk45KM7:TR?=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB5N{KyPEc,OjdyN{eyNlg9N2F-
Raji cells	MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MYW0PEBp	M2nSRWlEPTBiPTCxPU4{KM7:TR?=	M1fRVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGyNVc2Lz5{N{mxNlE4PTxxYU6=
Raji cells	M3GyXmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NVHqWJFSPDhiaB?=	NFXLOo9KSzVyIE2gNVkvOyEQvF2=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|Mkm0Okc,Ojh2M{K5OFY9N2F-
Raji cells	MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		M37mXVczKGh?	M1TpfGlEPTBiPTCxPU42KM7:TR?=	Mle3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xOFMoRjNyMEC2NVQ{RC:jPh?=
Raji cells	M1\mb2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MWC0PEBp	M3nub2lEPTBiPTCxPU42KM7:TR?=	NX3YZm1bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5OVYxOzdpPkK3PVU3ODN5PD;hQi=>
NAMALWA cells	M4TxSmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NH7WU5M4OiCq	MWnJR\|UxKD1iMUmuOkDPxE1?	MoLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xOFMoRjNyMEC2NVQ{RC:jPh?=
A2780 cells	MmDzR5l1d3SxeHnjbZR6KGG\|c3H5		MlO0N{Bl[Xm\|	MUHFR\|UxKD1iMkCuNUDPxE1?	NWD1bFBIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewO\|czOjhpPkK3NFc4OjJ6PD;hQi=>
Raji cells	NIXoWIlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NF24e2s4OiCq	M{XOeWlEPTBiPTCyNE45QCEQvF2=	M4XKV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUS2NVM3Lz5{OUG0OlE{PjxxYU6=
A549 cells	MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NW\hfohGPzJiaB?=	NXPXfnlnUUN3MDC9JFIyNjd7IN88US=>	Mnj2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5M{S1PFEoRjJ6N{O0OVgyRC:jPh?=
SW480 cells	NWPyO2RRS3m2b4TvfIlkcXS7IHHzd4F6		MXKzJIRigXN?	MkDBTWM2OCB;IEK1MlYh\|ryP	M3vKbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEe3NlI5Lz5{N{C3O\|IzQDxxYU6=
Ramos cells	MWfDfZRwfG:6aXPpeJkh[XO\|YYm=		M2\HT\|I1KGh?	NUP4W3JRUUN3MDC9JFI5NjdizszN	M2TrZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6Mke0Olc2Lz5{OEK3OFY4PTxxYU6=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	pEGFR(Tyr1068) / EGFR; PubMed: 28061447 Oncotarget Ibrutinib inhibitory effects on EGFRY1068 auto-phosphorylation in the HCC827 cell line at different time points by removal of drug after 4 h pretreatment. pBTK / pPLCγ2 / pAKT / pERK / pJNK; PubMed: 23940282 Blood Mino (left panel) or Jeko1 (right panel) cells pretreated with vehicle or ibrutinib 10, 100, or 1000 nM were either stimulated with anti-IgM, CXCL12, or CXCL13 or treated with medium (Med) for 15 minutes and then immunoblotted for pBTK, pPLCγ2, pAKT, pERK, and pJNK.	28061447 23940282
Immunofluorescence	CD11b; PubMed: 30231870 J Neuroinflammation BV2 microglial cells were pretreated with ibrutinib (1 μM) or vehicle (1% DMSO) for 30 min, followed by treatment with LPS (1 μg/ml) or PBS for 5.5 h and immunostaining with an anti-CD11b antibody. Scale bar = 20 μm. COX-2; PubMed: 30231870 J Neuroinflammation BV2 microglial cells were treated with vehicle (1% DMSO) or ibrutinib (1 μM) for 30 min, followed by PBS or LPS (1 μg/ml) for 5.5 h, and immunocytochemistry was conducted with anti-CD11b and anti-COX-2 antibodies.	30231870
ELISA	hTNFα; PubMed: 26627823 J Biol Chem PBMs were isolated and pretreated with 1, 5, or 10 μm ibrutinib (IB) or left untreated (UT, −). Pretreated PBMs were incubated for 24 h in 96-well plates precoated without (PBS) or with 10 μg/ml whole human IgG. Cleared supernatants were collected and analyzed by ELISA for TNFα (n = 3). IL-10; PubMed: 27792904 Virology LMP2A-negative (vector.1/.2) and -positive (express LMP2A) B cell lines were incubated in the absence or presence of increasing concentrations of Ibrutinib for 24 hours and supernatants were isolated for analysis using an IL-10 ELISA.	26627823 27792904

体内試験

In a collagen-induced arthritis model, Ibrutinib significantly reduces clinical arthritis scores reflecting paw swelling and joint inflammation by inhibiting B-cell activation. In a MRL-Fas(lpr) lupus model, Ibrutinib reduces renal disease and autoantibody production. ^[1] In an adoptive transfer TCL1 mouse model of CLL, Ibrutinib (25 mg/kg/day) causes a transient early lymphocytosis, and delays CLL disease progression. ^[4]

お薦めの試験操作（参考用のみ）

キナーゼ試験： ^[1]	- 合併 Kinase Assays : In vitro kinase IC50 values are measured using ³³P filtration binding assay after 1 hour incubation of kinase, ³³P-ATP, Ibrutinib, and substrate [0.2 mg/mL poly(EY)(4:1]. Assays are performed at Reaction Biology.
細胞試験： ^[2]	- 合併細胞株： Chronic lymphocytic leukemia (CLL) cells 濃度： 0.01-100 μM 反応時間： 48 hours 実験の流れ： MTT (3'[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assays are performed to determine cytotoxicity. Briefly, cells (CLL B cells or healthy volunteer T cells or NK cells) are incubated for 48 hours with different concentrations of Ibrutinib, or vehicle control. MTT reagent is then added, and plates are incubated for an additional 20 hours before washing with protamine sulfate in phosphate-buffered saline. Dimethyl sulfoxide is added, and absorbance is measured by spectrophotometry at 540 nm in a Labsystems plate reader. Cell viability is also measured at various time points with the use of annexin/PI flow cytometry. Data are analyzed with Expo-ADC32 software package. Results are expressed as the percentage of total positive cells over untreated control. Experiments examining caspase-dependent apoptosis includes the addition of 100μM Z-VAD. (参考用のみ)
動物試験： ^[1]	- 合併動物モデル： MRL-Fas(lpr) lupus model and collagen-induced arthritis model. 投薬量： ≤50 mg/kg 投与方法： Administered via p.o. (参考用のみ)

参考

[4] Ponader S, et al. Blood. 2012, 119(5), 1182-1189.

- 合併

溶解度 (25°C)

体外	DMSO	88 mg/mL (199.77 mM)
	Ethanol	45 mg/mL (102.15 mM)
	Water	Insoluble
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 5% DMSO+30% PEG 300+5% Tween 80+ddH2O 混合させたのち直ちに使用することを推奨します。	10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Ibrutinib (PCI-32765) SDFをダウンロードする

分子量	440.5
化学式	C₂₅H₂₄N₆O₂
CAS No.	936563-96-1
Storage	3 years-20°C powder 2 years-80°C in solvent
別名	N/A
Smiles	C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量

mg/kg

動物平均体重

投与体積（動物毎）

動物数

匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO+ % + % Tween 80+ % ddH₂O

計算リセット

計算結果:

投与溶媒濃度： mg/ml；

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL，注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。）

投与溶媒調製方法：μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04294641	Recruiting	Drug: Ibrutinib	Chronic GVHD	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	January 5 2021	Phase 2
NCT04665115	Not yet recruiting	Drug: Ibrutinib\|Other: Quality-of-Life Assessment	Asymptomatic COVID-19 Infection Laboratory-Confirmed\|B-Cell Neoplasm\|Chronic Lymphocytic Leukemia\|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma\|Mantle Cell Lymphoma\|Marginal Zone Lymphoma\|Small Lymphocytic Lymphoma\|Symptomatic COVID-19 Infection Laboratory-Confirmed\|Waldenstrom Macroglobulinemia	Academic and Community Cancer Research United\|National Cancer Institute (NCI)	December 31 2020	Phase 2
NCT04514393	Not yet recruiting	Drug: Methotrexate\|Drug: Ibrutinib\|Drug: Temozolomide	Primary Central Nervous System Lymphoma\|PCNSL\|Non Hodgkin Lymphoma	Huiqiang Huang\|Guangdong 999 Brain Hospital\|Nanfang Hospital of Southern Medical University\|Xian-Janssen Pharmaceutical Ltd.\|Sun Yat-sen University	December 1 2020	Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須
*大学・企業名:
*名前:
*電子メール:
*電話番号:
*内容:

よくある質問（FAQ）

質問1：
How to reconstitute the compound S2680 for in vivo studies?
回答：
For in vivo study, we suggest to use 5% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 10mg/ml.

研究分野別

製品類型

Ibrutinib (PCI-32765)

文献中Selleckの製品使用例(423)

製品安全説明書

Target Protein Ligand阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Ibrutinib (PCI-32765) SDFをダウンロードする

投与溶媒組成計算器(クリア溶液)

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2021-01-06)

技術サポート

よくある質問（FAQ）